Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Results available

Tranylcypromine Treatment of Bipolar Depression

NCT01430455
Conditions
Bipolar Disorder I or II
Interventions
Tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Completed Phase 2Phase 3 Interventional Results available

Psychotherapy for Bipolar II Depression, Pilot Study, Phase II

NCT00411463
Conditions
Bipolar II Disorder
Interventions
Interpersonal and Social Rhythm Therapy (IPSRT-BPII), Seroquel
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 4 Interventional Results available

Acute Psychotherapy for Bipolar II Depression

NCT01133821
Conditions
Bipolar Disorder, Depression
Interventions
IPSRT plus placebo (IPSRT-PLA), IPSRT plus quetiapine
Drug
Lead sponsor
Holly Swartz
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Bipolar Depression
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
56
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 29 more
Completed No phase listed Observational Accepts healthy volunteers

Microbiome of Depression & Treatment Response to Citalopram

NCT02330068
Conditions
Major Depressive Disorder, Bipolar I and Bipolar II
Interventions
citalopram
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Bipolar Disorder, Bipolar I Depression, Bipolar II Depression, Bipolar Depression, Depression, Major Depressive Episode
Interventions
Lithium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Ischemia, Stress, Mental
Interventions
Coronary CT Angiography, Mood Symptom Scale, Anxiety Symptom Scale, Chronic Stress Inventories, Psychosocial Function Questionnaires, General Health and quality of life questionnaires, Magnetic Resonance Imaging
Radiation · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions
Psilocybin, Therapeutic Support
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bipolar I Depression
Interventions
RG2417, Placebo
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 33 more
Conditions
Bipolar Disorder I or II With a Major Depressive Episode
Interventions
ALTO-100, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Chandler, Arizona • Phoenix, Arizona • Yuma, Arizona + 22 more
Conditions
Bipolar Disorder
Interventions
Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bipolar II Disorder
Interventions
Psilocybin therapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Interventions
NMRA-335140 80 mg, Placebo
Drug
Lead sponsor
Neumora Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more
Conditions
Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Conditions
Bipolar Disorder, Depression
Interventions
Fluoxetine, Lithium
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Bipolar Disorder, Major Depressive Episode
Interventions
7000lux broad-spectrum light, 50lux dim red light
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Bipolar Disorder
Interventions
MCN36 (nutritional supplement), Placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Conditions
Bipolar Depression
Interventions
Uridine
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Timeline
Started 2006
U.S. locations
11
States / cities
Stanford, California • Smyrna, Georgia • Indianapolis, Indiana + 8 more
Conditions
Mood Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar Disorder II, Persistent Depressive Disorder (Dysthymia), Cyclothymia
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
25 Years to 50 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Bipolar Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas